A patient with a neuroendocrine pancreatic tumor is on a monthly dose of octreotide administered by intramuscular (IM) injection. To report this service, is it appropriate to select the code based on the drug classification as a therapeutic and report code 96372 ? Or is it appropriate to select the code based on the intent as an anti-neoplastic and report code 96402 ? ...
Subscribe or sign in to view the full article.
Article Overview
This brief coding Q&A addresses how to think about reporting an intramuscular administration of octreotide for a patient with a neuroendocrine pancreatic tumor. It is aimed at coders, billing staff, and clinicians who need to understand the general CPT/HCPCS categories involved, the role of payer coverage, and the kind of administration complexity discussed in CPT Assistant guidance.
Why This Topic Matters
Correctly classifying drug administration services affects claim reporting and payer review. This article helps readers understand the general framework used to distinguish routine injection services from more complex administration categories.
What You Will Learn
- How this type of octreotide administration is discussed in relation to CPT and HCPCS reporting
- What general factors are considered when distinguishing routine injection services from higher-complexity drug administration services
- How payer-specific coverage considerations can affect reporting decisions
- What role CPT Assistant guidance plays in the discussion
Who Should Read This
- Medical coders
- Billing staff
- Physician practices
- Outpatient clinic staff
- Compliance teams
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com